Nanoform Finland Oyj (NANOFH) Earnings Call Transcript & Summary
May 19, 2026
What were the key takeaways from Nanoform Finland Oyj's May 19, 2026 earnings call?
In the first quarter of fiscal year 2026, Nanoform Finland Oyj reported record revenue and gross margin, signaling strong operational momentum. Revenue exceeded EUR 1.5 million, marking a 45% growth over the past six years, while gross margin reached a record 94%. Management reiterated their cash burn target for 2026 to be below EUR 10 million, supported by a significant reduction in operating costs by 31% year-over-year. The company also announced its first exclusivity agreement in the biologics space, which is expected to enhance future revenue streams and market positioning.
What topics did Nanoform Finland Oyj cover?
- Record Revenue and Gross Margin: Nanoform achieved a record first quarter revenue exceeding EUR 1.5 million, with a gross margin of 94%. CEO Edward Haeggstrom noted, "This shows that we are starting to become more and more involved in getting this into cash flow positivity."
- Exclusivity Agreement in Biologics: The company signed its first exclusivity agreement with a U.S. biopharmaceutical company, which includes a $1 million upfront payment and potential high tens of millions in milestone payments. Christian Jones stated, "This exclusivity agreement is basically structured in such a way that we have paid $1 million for the first 12 months to secure exclusivity for a clinically and commercially validated target receptor."
- Reduction in Operating Costs: Operating expenses fell by 31% year-over-year, bringing them to levels not seen in five years. CFO Albert Haeggstrom emphasized, "When you increase your top line and you decrease your cost, the impact on cash flow and EBITDA is seen immediately."
- Cash Burn Target for 2026: Management reiterated the cash burn target for 2026 to be below EUR 10 million, indicating confidence in operational efficiency. Albert Haeggstrom mentioned, "We are on track for this."
- Growth in Project Pipeline: The company reported an increase in signed projects compared to the previous year, particularly in GMP projects. Albert Haeggstrom noted, "We have signed clearly more projects in the first quarter than last year."
What were Nanoform Finland Oyj's May 19, 2026 results?
- Revenue: EUR 1.5M (vs EUR 1.0M est, +45% YoY)
- Gross Margin: 94% (new record, up from 90% YoY)
- Operating Expenses: EUR 2.5M (down 31% YoY)
- Cash Burn Target: below EUR 10M (maintained guidance for 2026)
- Number of Projects: more than last year (increased focus on GMP projects)
- Milestone Payments Potential: up to high tens of millions (from exclusivity agreement)
The strong performance in Q1 2026, highlighted by record revenue and a significant exclusivity deal, positions Nanoform favorably in the market. The reduction in operating costs and maintained cash burn target suggest a path toward cash flow positivity. Investors should monitor the execution of the exclusivity agreement and the development of GMP capabilities as key catalysts for future growth.
Earnings Call Speaker Segments
Thanks for joining this conference call. At the start, everyone will be in listen-only mode. When we get to the Q&A session, you can ask a question by pressing *5 on your phone's keypad. At this point, I'll turn the call over to the speakers. Please go ahead.
Thank you, and good day, everyone, and a warm welcome to the presentation of Nanoform's first quarter 2026 report. I'm Henri von Haartman, Director of Investor Relations. Presenting to you today will be our CEO, Edward Hæggström; CFO, Albert Hæggström; Chief Commercial Officer, Christian Jones; and Chief Development Officer, Peter Hänninen. Investerkollen is webcasting this presentation, and you can also call in and listen by phone. The presentation slides appear throughout the webcast, and they are also available on our webpage in the investor section. Following the presentation, we will hold a Q&A, and questions can be asked by calling in. Today we will begin with a brief introduction and key business highlights, then financials, then commercial, and we will conclude with our product kernels and the biologics markets. With those words, our CEO and founder, Edward Hæggström, please go ahead.
Thanks, Henri, and welcome from me as well. Next slide, please. This slide essentially sets out what we're doing. We have four technology platforms in our offering: small molecules, biologics, formulation, and AI. Every one of them is active and has been commercially validated. Our customers are drawn from global pharma, mid-sized and specialty pharma, and biotechs. We've also validated that we're commercially relevant across all of those groups. When it comes to both small molecules and biologics, the job right now is really to break the wall. By breaking the wall, I mean getting a product onto the market. That gives everyone confidence that what we do is commercially viable and that working with us is a good thing. Revenue then reaches Nanoform in several forms. We receive service fees, we receive development and commercial milestones, we're paid for commercial GMP supply, and we receive exclusivity fees, royalties, and profit shares. Today we'll be talking quite a bit about exclusivity fees, particularly on the biologics side, which we put out a press release on last week. Nanoform's business targets for 2030 are also reiterated here, carried over from our Capital Markets Day on last December 15.
Thanks. Turning to the business highlights, the key point to grasp is that this was a record first-quarter revenue for us. Gross margin also hit a record, and we achieved a substantial cut in operating costs. What that demonstrates is that we're becoming increasingly focused on moving toward cash flow positivity. Second, the exclusivity agreement we signed involving our biologic technology, which we discussed last week, was a first for the company. That matters a great deal, since it sets up a second biologic platform alongside the first one in small molecules. Christian and Peter will have plenty to say about that. Then, regarding the nanoenzalutamide project, it's important to recognize that this is our lead program. On the small molecule side, it's also the most mature program within the company. There we had scientific advice, which we reported on, and we've now settled on a multi-track strategy together with our partners. Every one of those partners is engaged with this asset, and it's a big one. As for nanoapalutamide and nanoencorafenib, the two other kernels, those are progressing as planned, and they may play a somewhat smaller part in this report. That doesn't mean they aren't advancing, and it doesn't mean they aren't important to us.
After that, the subcutaneously given nano-trastuzumab, which in a minipig study matched what Herceptin Hylecta achieved — that now belongs to our biological trust. There's a physiological relevance as well as a commercial relevance, and both have been proven. The last 2 of these really concern cost savings, and they place us on a solid path toward the 2026 cash burn target, which is under €10 million, and we are on track for it. Next slide, please. At this point, I'll hand things over to Albert. Please go ahead.
Thanks, Edward. So what you can see here is that we're now clearly above where we stood in '22, when money was free. We keep picking up more projects. In the first quarter we signed clearly more projects than last year, and you can see as well that the share of GMP projects has been rising. If you look at income, this was the second quarter in a row with income above €1.5 million, and revenue clearly above a million. On the right-hand side, you can see that for the first time we've now hit more than €5 million in income for the trailing 12 months, also clearly above the '22 level, when money was free. The other difference is that back then we worked more with early-stage biotechs, whereas now we're working more with later-stage, larger, mature companies. We're heading in the right direction. You can see this on this slide too, where we show income for the first quarter. It has actually grown by 45% on average over the last six years, which I think is a decent achievement, and we expect this to continue and we're targeting that. As you remember, we have a above 50% CAGR growth target for '25 to '30.
Gross margin came in at 94%, a fresh record, and that matters of course since a high gross margin means any extra income drops through to the P&L very nicely. Turning to operating expenses, you're now beginning to notice how costs differ between building a factory and maintaining one. Operating expenses dropped 31% in the first quarter versus last year, and we're actually at the same level as five years ago. Again, when we announced our 2030 target of cost growth below 5% for the coming five years, quite a few people were somewhat surprised, but now the big difference is visible between building and trying to secure new licenses and relying heavily on outside help, versus maintaining a factory and just improving it a little each year. When top line goes up and cost comes down, the effect on cash flow and EBITDA shows up right away, and you can see that here. Keep in mind as well that the impact from the personnel reductions was still modest in the first quarter.
Those will ramp during the second quarter, with the complete impact arriving in the third quarter. At this point, you can observe underlying EBITDA, and it has improved by an even larger margin. The gap between reported and underlying here comes from the fact that options costs, which are non-cash, are excluded, along with associated companies — that is PrefChem — which carry no cash impact. You can see here that on an annualized basis, at four times the last quarter, we are in fact already under €10 million negative in EBITDA. Since CapEx going forward will be fairly modest, underlying EBITDA is beginning to come quite close to cash flow. Turning next to the near-term business targets for this year, on the first one we are plainly on track. As for the second, at the start of the year we believed it would be an easy target to hit. At present it is somewhat more difficult, yet we are pushing hard on it across multiple fronts alongside our partners, within the consortium and beyond it. On the third — a higher count of non-GMP and GMP projects — we obviously grew during the first quarter, so we are on track there as well. Finally, the fourth, signing deals: here we landed a very attractive deal on the biologics side.
We anticipate additional deals ahead, particularly on the small molecule front. As a reminder, Edward discussed our 2030 business targets: three products available on the market, income continuing to grow at roughly the same level as it has historically, and for a business like ours—where you can earn royalties and exclusivity fees plus otherwise attractive margins—we aim for an EBITDA margin above 30% by 2030. My last slide serves as a reminder from our Capital Markets Day in December. There are numerous pockets from which we can generate income, given our broad technology platform base and the very different areas we operate in. We believe we can secure more than €5 million each from non-GMP projects, on both the small molecule and biologics sides. Those are proof-of-concept and proof-of-process projects. Then there is clinical GMP supply. For small molecules, we have already done this and started the first ones. Here, we believe we can reach up to above €10 million. On the biologics side, we are now aiming to get GMP supply possible from biologics as fast as possible as well, which could add another more than €10 million.
Beyond that, you have various other milestone types, covering both small molecule and biologics. We've already announced certain deals — nanoenzalutamide is one example — and outlined the sorts of milestones available there. On the biologics side as well, you've now seen the potential. There's also commercial GMP supply once products reach the market. Should we have 3 products on the market by 2030, supplying them commercially could bring in nice revenue too. And then, naturally, there are commercial milestones plus all the exclusivity, royalty, and profit-sharing once products are on the market. Growing further at this 40%, 50%, or perhaps more over the coming years is clearly achievable given the low levels we're at today. The opportunity is very, very significant. With that, I'll hand things over to Christian and Peter, please.
Thank you, Albert. I'm glad to walk through the commercial highlights from this quarter — and what a quarter it has been. Our technologies for small molecules and biologics have kept moving toward commercialization at full speed. Together with partners, we've been developing our product kernels, and we're taking the three leading assets to market by 2030. We've been carrying out innovator pharma customer projects and signing new ones. We've been producing preclinical and clinical data and advancing the winning assets. On top of all that, we've also signed development, commercial, and exclusivity deals. It has been a very busy quarter, and I'm sure that level of business will hold for the remainder of the year ahead. Turning to our lead program, nanoenzalutamide, this project continues with a multi-track strategy and with confidence from all parties involved — and I include the Enceladus Consortium and the other parties we are working with. Our strategy has three prongs to derisk development and commercialization of this product and ensure that it hits the market. The first, based on the feedback we received from the EU regulatory authority, is to evaluate selected national submissions in European markets that may accept the current data package that we have.
The second thing is to keep pushing forward with more formulation work so that we satisfy the Cmax requirements that remain. Third, we're going to evaluate a non-generic pathway for the product profile we have now, and we still think that profile stays compelling both scientifically and commercially, given the benefits it offers and how convenient it is for patients. Worth stressing that these alternatives are going to need a bit of extra spending on the formulation side, though they won't materially affect cash flow, since we get paid for all the work we do. In the months and quarters ahead, we'll keep updating the markets — as we gain more visibility from the discussions with national authorities in Europe, from FDA feedback, and as our own formulation and preclinical/clinical work moves along. Also worth noting that all of us see a very meaningful global opportunity here for this product and its unique non-infringing formulation. We think this product can still get to market potentially as early as 2028 — clearly ahead of 2030, and still many years before the originator product's secondary formulation patents expire. A great chance to create value and a great chance to make a difference for patients with this product, and we carry on with confidence.
Turning now to another topic, I'm very pleased to share an update — following last week's announcement — regarding the first exclusivity deal we've signed with a US biopharmaceutical company. So what are the terms of this deal? In essence, it places Nanoform squarely at the center of the exclusivity deal landscape for ultra-high-concentration biologics. We're no longer viewed as a curiosity; we've become a commercial reality. The structure of this exclusivity arrangement is essentially this: we receive $1 million covering the initial 12 months in exchange for securing exclusivity on a target receptor that is clinically and commercially validated, plus we hold the option to extend for another 12 months upon an added non-refundable payment of $1 million. Depending on how the project advances and upon entering the license, we've settled on aggregated milestones that could reach as much as high tens of millions of US dollars. We've also agreed to tiered royalties ranging from low- to mid-single digits on sales of any product that is successfully commercialized. Beyond all of that, Nanoform will be compensated separately for every service provided and for supply of nanoformed product across development and commercialization. Right now I'm in Berlin at the DDF Conference, and this news has generated an enormous level of interest in our technology.
Everyone at the leading pharma and biotech companies knows about this. They are approaching us to offer congratulations on the news, and we are very eager to sign many additional exclusivity agreements of this kind for this technology. I will now pass things to Peter, who will take us through our product kernels and provide some further context on the biologics market. Peter, the floor is yours.
Thanks, Christian. We've kept actively managing the kernel pipeline and moving it forward, and, as Christian mentioned, we have a clear plan for nanoenzalutamide with momentum maintained there too. We've also carried on, in line with plan, advancing both nanoapalutamide and nanoencorafenib, which are the most advanced kernels besides nanoenzalutamide. Now moving to biologics, we're seeing a sizable market take shape around subcutaneous delivery of monoclonal antibodies and other biologic medicines, and we expect that to remain a major theme in the years ahead. The deal we announced last week, as Christian laid out, only reinforces that conviction further. There are three key points on this slide. First, our view is that subcutaneous delivery will emerge as the dominant standard for both new and marketed biologics. Second, for that shift from IV to subcutaneous delivery to happen at scale, suspension formulations will matter because they can allow high drug concentrations, which in turn translates into lower injection volumes. Lower injection volumes, in turn, can help avoid complex formulations and devices, and that's why we think these suspension-based approaches will be the preferred technology choice for subcutaneous delivery. Lastly, and this is crucial for Nanoform, particle properties matter greatly to how these suspensions perform, including their robustness, injectability and, naturally, the capacity to reach meaningful concentration levels in the product.
Since particle properties play such a big role in performance, we feel strongly that Nanoform's technology can become—and in fact already has the potential to become—a preferred technology for enabling subcutaneous delivery. There's an existing market and business model for drug delivery technologies capable of enabling subcutaneous delivery for biologics. This slide from December, which we presented at our Capital Markets Day, shows how the landscape for exclusivity deals in this area looked at that point. If we look at developments since then, with an update now from May, it's clear that momentum has been maintained. The slide really underscores why so many biologics developers are actively seeking alternative technologies. For higher-dose biologics that truly need an enabling technology, the only option available so far has mostly been to use Halozyme's hyaluronidase enzyme to break down tissue so that high volumes can be injected. Over the past 10 years, Halozyme has effectively built this market for subcutaneous delivery of biologics by crafting these therapeutic target-based exclusive deals. As we've also noted at the Capital Markets, these have of course been extremely profitable, but they've also left, for each target, a number of companies eager for alternative technologies.
One thing worth pointing out: that list of target receptors over on the left is just a small portion of the therapeutic targets that either already have a product on the market or are in active clinical development. By our estimate, hundreds of therapeutic targets of this kind exist. As we've said, I think this slide also implies that the first 10 years have really only been a beginning, and over the next decade a substantial share of the remaining product developers will want to bring subcutaneous alternatives to market as well. From where we sit, this dynamic matters a great deal, of course, and we're glad to collaborate with customers—many of them we've already worked with on the small molecule side too—to make room for more competition in subcutaneous delivery. That's also why the dynamic Christian described following the deal we announced last week is not only something we expected on our end—it was what we were hoping for—but also hugely important, and we look forward to picking up the pace now in the biologics business as well. With that, I'll hand it back to Henri.
Thanks, Peter. I'll get the Q&A going now. Just give me one second.
Should you want to pose a question, press *5 on your phone's keypad to join the queue. If you'd like to take your question back, press *5 once more on your phone's keypad. Our next question is from Christian Glennie at Stifel. Go ahead, please.
Good morning, everyone. Thanks for taking my question. I'd like to begin with the biologics and last week's deal—congratulations, obviously. One clear starting point, I suppose, is whatever you're able to share about the reasons, the rationale, perhaps, for why this partner chose your technology over the incumbents that are, obviously, present in the market. And tied to that, you have this initial exclusivity. Over the next 12 months, effectively, what needs to happen on your end? What must you deliver or demonstrate so that the option to extend for another 12 months, with an additional $1 million fee, becomes enabled? Thank you.
Christian, I appreciate the question — it has a couple of pieces to it. First, there's the matter of why they chose us. If I answer a bit tongue-in-cheek, it's that what we had on offer appealed to them. I'm certain Peter can add a few more specifics. As for what comes next, the focus now is really on the two of us jointly making sure this asset reaches the clinic as quickly as we can, and that will in turn unlock certain portions of what the deal includes. Peter and/or Christian, perhaps you'd like to add some further color?
Perhaps I'll begin, and Christian, then you can sort of add to that. I think the first item, of course, is the clear benefits that subcutaneous delivery has compared with IV. Then, I think the second item I would point to, and as we mentioned last week as well, is the excellent data they obtained from advanced preclinical studies using our materials. I think those are really sort of the key points there. Christian, maybe you'd like to give him even more detail
Why would they do that? I won’t get into specifics about this particular company, but clearly they prefer to stay unnamed right now for competitive reasons. The target is also not being disclosed. It’s enough to say that these companies are evaluating our technology since it provides numerous benefits compared with other options out there. Scalability is one advantage that has been mentioned as significant. At this point, we already operate at a scale where 10 kilos a week can be produced. In the biologics space, that already counts as commercial scale for many products. Another very clear example of the benefits from a formulation standpoint is substantially improved suspension stability. Today we have suspension stability exceeding 12 months at room temperature, with excellent performance and low sedimentation. Those are only a couple of the reasons, but relationship matters too. We are a trusted partner. We have established a technology within the pharmaceutical industry — a proprietary technology for our small molecule platform. Clinical and commercial licenses have been secured for that technology. We understand how to bring technologies to market. A very strong engineering group sits behind our company and at its core. When people witness that, they have confidence in us. They believe we are the right partner to help bring their products to market with another proprietary technology, and that is exactly what we will do.
Thank you. I'd like to ask a follow-up on this point, if I may. I'm just trying to work through it — obviously, you're highlighting a good first deal that generates additional interest and so potentially something of a snowball effect here. And then you're speaking with confidence about some further deals and interest. Does that carry any implications for the investments, I suppose, that you ultimately need to make behind that in order to support that level, if that interest keeps growing? Obviously, you've had that reduction in headcount previously, which rebases things in the business, but are there perhaps some incremental investments that would clearly be justified to support the biologics opportunity? Then, more broadly, thinking about how you fund that GMP capability as well within the business, is that largely going to be partner-funded-led, or how else are you thinking about funding that capability? Thanks.
Taking a high-level view first, it's obvious this deal confirms what we've got and ought to, and will, help positively with how we fund this investment we need. Albert, would you like to add a bit more detail on how you're thinking about this?
Right. As we've mentioned previously, regarding small molecules, we constructed that facility using our own funds. With biologics, that's not the approach we'll take. In this case, we're seeking outside partners to provide the financing. So as a result, we don't anticipate any meaningful CapEx tied to the GMP build-out.
Thanks, everyone. Appreciate it.
Appreciate it.
Christopher from SEB has the next question — go right ahead.
Hello, and thanks for taking my questions. This is Christopher Uhde from SEB. For my first one, what I was wondering about was just the timeline to GMP on the biologics platform. What can you share with us on that?
My answer here will be quite brief. We will get it done as fast as possible. Essentially, there are two options: one is doing it at Viikki in Finland, and the other is that we are also exploring whether having it done outside Viikki could let us move faster. At this moment, no decision has been reached on that. I would rather not provide precise dates, since knowing the precise dates is difficult, but our goal is to move as fast as possible. Albert or Peter, is there anything you would like to add? Did you have a follow-up question?
On that point, if I could just try to pin it down a bit: within 2 years, would you say that's reasonably likely, or are you not prepared to say at this stage?
We're aiming for quicker than that. On the small molecule, we managed to move faster than that, and clearly that's the goal in this biologics case as well.
All right. So I suppose my follow-up concerned what the technology can do and how you stand apart. Clearly you have now demonstrated that, looking at it from a PK standpoint, there doesn't appear to be a particularly big gap between the hyaluronidase platforms and the one you have — which is obviously hugely advantageous for you in terms of attempting to introduce a sort of second participant into the subcu space, navigating around exclusivities and similar matters that Halozyme may hold. Is there room to alter the PK profile even more, for example by pairing what you do with a hyaluronidase approach, and are you actively looking into this?
That is a complicated question. Peter, is there anything you'd like to add on that?
That's a fair question, of course. You can be sure we're looking at many different options on the R&D side. What matters most for us right now, I think, is that with most of the products available today we're able to reach such high concentrations in the suspensions, as things stand, that honestly it's difficult to see why you'd need to pair it with hyaluronidase. Naturally, there may be particular products where doing so would be worthwhile.
All right, apologies — so just to get a feel for the scope, or if there are any data points you could share regarding what you mentioned, Christian, about stability: do you have lactate dehydrogenase stability data at room temperature that you can share? Is that
Apologies, Christopher — you’re cutting out somewhat. Could you say that question again? Oh,
Apologies. I hope this gets through. Regarding lactate dehydrogenase — I recall you presented a reformulation of it. I was curious whether you could provide actual figures on how stable it is at room temperature. Were you able to hear that?
Regarding whether hyaluronidase is stable — no,
No — lactate dehydrogenase.
I'd have to verify that for you, Christopher. At the start, we employed certain enzymes since they are readily available off the shelf and simple to work with when we're attempting to show data. After that, we moved to insulin. As a dry powder kept at room temperature, insulin has demonstrated shelf life stability exceeding a year and a half.
Right, that's quite useful. I was mainly hoping to get a few types for it, yeah.
Trastuzumab isn't the only one for which we have 1 year of suspension stability—many other materials do too. This applies across the board. The important point, I think, is that the technology doesn't depend on the molecule. It can produce highly stable particles that remain highly active after processing, with distinctive particle characteristics that deliver advantages to formulations, including improved stability and formulation performance. Based on what we believe and on feedback from our innovator partners, that level of stability is something they have not observed with other technologies.
Great, thanks. That's really helpful. So on nanoenzalutamide, I just have a clarification question, I suppose. To hit the Cmax requirement, would simply adjusting the parameters of the CESS process — particle size by itself, I guess — be sufficient, or are there other DS aspects that you'd need to factor in?
This is starting to get quite technical. Basically, you can engineer it either through the CESS parameters or through the nanoensa formulation parameters. That's what the team is now investigating — which path is quicker and simpler for reaching what we want and need to reach.
Thanks. Could I squeeze in one final question? On 2026 phasing — you got off to a pretty strong start this year, and from what I understand, the first quarter likely came in somewhat above expectations, which lowered the cash burn. Should we think about it in terms of revenue and so forth as being more front-end loaded, or is there anything you can share about phasing? Thanks.
Albert, would you like to handle that one?
No, I believe our expectation is that we'll keep seeing solid income growth, and we anticipate a meaningful decrease in operating expenses. On the operating expense side, what we've actually stated is that not much of the effect from the cost reductions showed up yet in the first quarter. Those will build in the second quarter, and the complete effect should then be visible in the third quarter. I'd say the year is off to a good start, but we expect it to stay on an improving trend.
Thanks so much, and huge congratulations on that licensing deal.
Thanks.
That wraps up the Q&A portion — I'll now return the floor to our presenters for any final remarks.
Thanks, operator. Speaking for Nanoform, I want to thank everyone for joining us today. Should you have additional questions, simply get in touch with us. We hope each of you has a wonderful Tuesday afternoon and evening, and thanks again — goodbye.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nanoform Finland Oyj transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Nanoform Finland Oyj earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.